CCND3 Positive
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT01880567) | M.D. Anderson Cancer Center | 2013-07-15 |
Track CCND3 Positive automatically
Every clearance here is in the API, with alerts when new ones post.